Target Price | $505.73 |
Price | $503.20 |
Potential | 0.50% |
Number of Estimates | 26 |
26 Analysts have issued a price target Vertex Pharmaceuticals 2026 . The average Vertex Pharmaceuticals target price is $505.73. This is 0.50% higher than the current stock price. The highest price target is $615.00 22.22% , the lowest is $330.00 34.42% . | |
A rating was issued by 35 analysts: 20 Analysts recommend Vertex Pharmaceuticals to buy, 13 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2026 of 0.50% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase. |
28 Analysts have issued a sales forecast Vertex Pharmaceuticals 2025 . The average Vertex Pharmaceuticals sales estimate is $12.0b . This is 8.97% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $12.5b 13.38% , the lowest is $11.8b 6.97% .
This results in the following potential growth metrics:
2024 | $11.0b | 11.64% |
---|---|---|
2025 | $12.0b | 8.97% |
2026 | $13.1b | 9.48% |
2027 | $14.3b | 9.32% |
2028 | $15.5b | 8.37% |
2029 | $17.2b | 10.70% |
8 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2025. The average Vertex Pharmaceuticals EBITDA estimate is $5.6b . This is 22,852.37% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.1b 24,966.71% , the lowest is $4.8b 19,847.65% .
This results in the following potential growth metrics and future EBITDA Margins:
2024 | $4.6b | 2.39% |
---|---|---|
2025 | $5.6b | 21.67% |
2026 | $6.6b | 19.46% |
2027 | $7.5b | 12.83% |
2028 | $8.3b | 10.45% |
2029 | $9.1b | 10.25% |
2024 | 41.56% | 8.29% |
---|---|---|
2025 | 46.41% | 11.67% |
2026 | 50.64% | 9.11% |
2027 | 52.26% | 3.20% |
2028 | 53.27% | 1.93% |
2029 | 53.05% | 0.41% |
19 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Vertex Pharmaceuticals net profit estimate is $4.1b . This is 830.76% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.7b 927.27% , the lowest is $3.6b 734.55% .
This results in the following potential growth metrics and future Net Margins:
2024 | $-534m | 114.97% |
---|---|---|
2025 | $4.1b | 872.92% |
2026 | $4.7b | 14.15% |
2027 | $5.2b | 10.87% |
2028 | $6.3b | 19.89% |
2029 | $6.8b | 8.84% |
2024 | -4.87% | 113.41% |
---|---|---|
2025 | 34.51% | 809.29% |
2026 | 35.98% | 4.26% |
2027 | 36.49% | 1.42% |
2028 | 40.37% | 10.63% |
2029 | 39.69% | 1.68% |
19 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals EPS is $16.08 . This is 830.91% higher than earnings per share in the financial year 2024. The highest EPS forecast is $18.20 927.27% , the lowest is $13.96 734.55% .
This results in the following potential growth metrics and future valuations:
2024 | $-2.08 | 114.97% |
---|---|---|
2025 | $16.08 | 873.08% |
2026 | $18.35 | 14.12% |
2027 | $20.35 | 10.90% |
2028 | $24.39 | 19.85% |
2029 | $26.55 | 8.86% |
Current | -228.55 | 878.71% |
---|---|---|
2025 | 31.30 | 113.70% |
2026 | 27.42 | 12.40% |
2027 | 24.73 | 9.81% |
2028 | 20.63 | 16.58% |
2029 | 18.95 | 8.14% |
Based on analysts' sales estimates for 2025, the Vertex Pharmaceuticals stock is valued at an EV/Sales of 10.43 and an P/S ratio of 10.80 .
This results in the following potential growth metrics and future valuations:
Current | 11.37 | 17.95% |
---|---|---|
2025 | 10.43 | 8.26% |
2026 | 9.53 | 8.66% |
2027 | 8.72 | 8.52% |
2028 | 8.04 | 7.72% |
2029 | 7.26 | 9.67% |
Current | 11.76 | 9.91% |
---|---|---|
2025 | 10.80 | 8.23% |
2026 | 9.86 | 8.66% |
2027 | 9.02 | 8.52% |
2028 | 8.32 | 7.72% |
2029 | 7.52 | 9.67% |
Vertex Pharmaceuticals...
Analyst | Rating | Action | Date |
---|---|---|---|
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Feb 20 2025 |
Canaccord Genuity |
Sell
➜
Hold
|
Upgrade | Feb 12 2025 |
RBC Capital |
Sector Perform
➜
Sector Perform
|
Unchanged | Feb 11 2025 |
Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Feb 11 2025 |
Barclays |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Feb 11 2025 |
HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Feb 11 2025 |
Cantor Fitzgerald |
Overweight
➜
Overweight
|
Unchanged | Feb 11 2025 |
Analyst Rating | Date |
---|---|
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Feb 20 2025 |
Upgrade
Canaccord Genuity:
Sell
➜
Hold
|
Feb 12 2025 |
Unchanged
RBC Capital:
Sector Perform
➜
Sector Perform
|
Feb 11 2025 |
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Feb 11 2025 |
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
|
Feb 11 2025 |
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Feb 11 2025 |
Unchanged
Cantor Fitzgerald:
Overweight
➜
Overweight
|
Feb 11 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.